The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Open accessAbstract
BACKGROUND: The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. METHODS: A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to 32 mg per day), quetiapine (200 to 800 mg per day), or risperidone (1.5 to 6.0 mg per day) for up to 18 months. Ziprasidone (40 to 160 mg per day) was included after its approval by the Food and Drug Administration. The primary aim was to delineate differences in the overall effectiveness of these five treatments. RESULTS: Overall, 74 percent of patients discontinued the study medication before 18 months (1061 of the 1432 patients who received at least one dose): 64 percent of those assigned to olanzapine, 75 percent of those assigned to perphenazine, 82 percent of those assigned to quetiapine, 74 percent of those assigned to risperidone, and 79 percent of those assigned to ziprasidone. The time to the discontinuation of treatment for any cause was significantly longer in the olanzapine group than in the quetiapine (P<0.001) or risperidone (P=0.002) group, but not in the perphenazine (P=0.021) or ziprasidone (P=0.028) group. The times to discontinuation because of intolerable side effects were similar among the groups, but the rates differed (P=0.04); olanzapine was associated with more discontinuation for weight gain or metabolic effects, and perphenazine was associated with more discontinuation for extrapyramidal effects. CONCLUSIONS: The majority of patients in each group discontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reasons. Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone. Olanzapine was associated with greater weight gain and increases in measures of glucose and lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An example of an early precursor to the SMART is the Clinical Antipsychotics Trial of Intervention Effectiveness (CATIE) [54] in chronic schizophrenia.”
From Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research (2014) · cites this paper as [54]
In the citing paper
“In schizophrenia, for example, recent studies have shown that since the introduction of second-generation antipsychotics, treatment efficacy has only marginally improved over traditional dopamine D-2 antagonists, which were introduced 50 years ago (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“While effective in reducing the positive symptoms, the cognitive dysfunctions and negative symptoms, two major determinants for outcome and level of functioning, remained unchanged in the large majority of patients.”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
In the citing paper
“Over the last 50 years, the pharmacological therapy of schizophrenia was based mainly on the dopamine hypothesis and made little progress (Lieberman et al., 2005”
From Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks (2012) · cites this paper as Lieberman et al., 2005
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Discovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Geddes, J. R., Freemantle, N., Harrison, P. J., & Bebbington, P. (2000) · BMJ · doi:10.1136/bmj.321.7273.1371 · Cited by 1,056
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
Davis, J. M., Chen, N., & Glick, I. D. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.6.553 · Cited by 1,022
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Self-citationLeucht, S., Pitschel‐Walz, G., Abraham, D., & Kissling, W. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00105-4 · Cited by 795
Cited by
Sorted by citations
Items 601–700 of 1,049
Sohn, M., Moga, D. C., Blumenschein, K., & Talbert, J. (2016) · Medicine · doi:10.1097/md.0000000000003784 · Cited by 102
Francey, S. M., Nelson, B., Thompson, A. D., Parker, A. G., Kerr, M., Macneil, C. A., Fraser, R., Hughes, F., Crisp, K., Harrigan, S., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.02.1071 · Cited by 102
Bugarski‐Kirola, D., Iwata, N., Sameljak, S., Reid, C., Blaettler, T., Millar, L., Marques, T. R., Garibaldi, G. M., & Kapur, S. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30344-3 · Cited by 102
Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., ANDERSON, R., Zablotsky, B., WILLIAMS, E., McNamara, N., Jackson, J. A., Ritz, L., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31807083fd · Cited by 102
Self-citationHow antipsychotics work—From receptors to reality
Kapur, S., Agid, O., Mizrahi, R., & Li, M. (2006) · NeuroRx · doi:10.1016/j.nurx.2005.12.003 · Cited by 102
Cooper, G. D., Pickavance, L. C., Wilding, J. P. H., Harrold, J. A., Halford, J. C. G., & Goudie, A. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106069637 · Cited by 102
Polymorphisms of the HTR2C Gene and Antipsychotic-Induced Weight Gain: An Update and Meta-Analysis
Sicard, M. N., Zai, C. C. H., Tiwari, A. K., de Souza, R. P., Meltzer, H. Y., Lieberman, J. A., Kennedy, J. L., & Müller, D. J. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.123 · Cited by 102
Self-citationGirgis, R. R., Javitch, J. A., & Lieberman, J. A. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.40 · Cited by 102
Self-citationIncreased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men
Fountaine, R. J., Taylor, A. E., Mancuso, J. P., Greenway, F. L., Byerley, L. O., Smith, S. R., Most, M. M., & Fryburg, D. A. (2010) · Obesity · doi:10.1038/oby.2010.6 · Cited by 102
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J. B., et al. (2006) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.4.4.539 · Cited by 102
Self-citationRosenheck, R. A., Mueser, K. T., Sint, K., Lin, H., Lynde, D., Glynn, S. M., Robinson, D. G., Schooler, N. R., Marcy, P., Mohamed, S., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.09.024 · Cited by 102
Self-citationThe NIMH-CATIE Schizophrenia Study: What Did We Learn?
Lieberman, J. A., & Stroup, T. S. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11010039 · Cited by 102
Self-citationFindling, R. L., Johnson, J. L., McClellan, J., Frazier, J. A., Vitiello, B., Hamer, R. M., Lieberman, J. A., Ritz, L., McNamara, N. K., Lingler, J., et al. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.03.013 · Cited by 101
Self-citationTargeting the CNS to treat type 2 diabetes
Sandoval, D. A., Obici, S., & Seeley, R. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2874 · Cited by 101
Chen, Y., & Briesacher, B. A. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.006 · Cited by 101
Antipsychotic-induced extrapyramidal symptoms and their management
Dayalu, P., & Chou, K. L. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.9.1451 · Cited by 101
Methodological Issues in Current Antipsychotic Drug Trials
Leucht, S., Heres, S., Hamann, J., & Kane, J. M. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm159 · Cited by 101
Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis
Uchida, H., Suzuki, T., Takeuchi, H., Arenovich, T., & Mamo, D. C. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp149 · Cited by 101
Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100
Self-citationLevitt, P. R., Ebert, P. J., Mirnics, K., Nimgaonkar, V. L., & Lewis, D. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.028 · Cited by 100
Silva, A. C., Amaral, M. H., González‐Mira, E., Santos, D. F. G., & Ferreira, D. (2012) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2012.01.014 · Cited by 100
Amann, L. C., Gandal, M. J., Lin, R., Liang, Y., & Siegel, S. J. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0152-4 · Cited by 99
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
The Role of Phosphodiesterases in Schizophrenia
Siuciak, J. A. (2008) · CNS Drugs · doi:10.2165/0023210-200822120-00002 · Cited by 99
GLT-1 transporter: An effective pharmacological target for various neurological disorders
Soni, N., Reddy, B. V. K., & Kumar, P. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.10.001 · Cited by 99
Gallini, A., Andrieu, S., Donohue, J. M., Oumouhou, N., Lapeyre‐Mestre, M., & Gardette, V. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.09.003 · Cited by 99
Serious mental illness and medical comorbidities: Findings from an integrated health care system
Bahorik, A. L., Satre, D. D., Kline‐Simon, A. H., Weisner, C. M., & Campbell, C. I. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.07.004 · Cited by 99
Correll, C. U., Sikich, L., Reeves, G. M., Johnson, J. L., Keeton, C. P., Spanos, M., Kapoor, S., Bussell, K., Miller, L., Chandrasekhar, T., et al. (2020) · World Psychiatry · doi:10.1002/wps.20714 · Cited by 99
The Impact of Mental Illness Stigma on Psychiatric Emergencies
da Silva, A. G., Baldaçara, L., Cavalcante, D. A., Fasanella, N. A., & Palha, A. J. P. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00573 · Cited by 99
Lim, K., Peh, O. H., Yang, Z., Rekhi, G., Rapisarda, A., See, Y. M., Rashid, N. A. A., Ang, M. S., Lee, S.-A., Sim, K., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102732 · Cited by 99
The attitude of patients towards antipsychotic depot treatment
Heres, S., Schmitz, F. S., Leucht, S., & Pajonk, F. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3280c28424 · Cited by 99
Penn, D. L., Keefe, R. S. E., Thomas, S., Meyer-Kalos, P., Perkins, D. O., Losardo, D., & Lieberman, J. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.08.016 · Cited by 99
Self-citationIncreased cortical inhibition in persons with schizophrenia treated with clozapine
Daskalakis, Z. J., Christensen, B. K., Fitzgerald, P. B., Möller, B., FOUNTAIN, S., & Chen, R. E. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107084002 · Cited by 99
Nakamura, T., Kubota, T., Iwakaji, A., Imada, M., Kapás, M., & Morio, Y. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s95100 · Cited by 99
Prevention of suicide by clozapine in mental disorders: systematic review
Masdrakis, V. G., & Baldwin, D. S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.011 · Cited by 98
Weston–Green, K., Huang, X., Lian, J., & Deng, C. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.09.003 · Cited by 98
Dold, M., Samara, M. T., Li, C., Tardy, M., & Leucht, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009831.pub2 · Cited by 98
Involuntary Movement Disorders
(2007) · Elsevier eBooks · doi:10.1016/b978-141603074-4.10018-9 · Cited by 98
Grandl, G., Straub, L., Rudigier, C., Arnold, M., Wueest, S., Konrad, D., & Wolfrum, C. (2018) · The Journal of Physiology · doi:10.1113/jp275173 · Cited by 97
Meltzer, H. Y., Elkis, H., Vanover, K. E., Weiner, D. M., van Kammen, D. P., Peters, P., & Hacksell, U. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.07.029 · Cited by 97
Bernardo, M., Bioque, M., Parellada, M., Ruiz, J. S., Cuesta, M. J., LLerena, A., Sanjuán, J., Castro‐Fornieles, J., Arango, C., & Cabrera, B. (2012) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2012.11.001 · Cited by 97
Opportunities for Research and NIH
Collins, F. S. (2009) · Science · doi:10.1126/science.1185055 · Cited by 97
Standard and Higher Dose of Olanzapine in Patients With Schizophrenia or Schizoaffective Disorder
Kinon, B. J., Volavka, J., Stauffer, V. L., Edwards, S., Liu‐Seifert, H., Chen, L., Adams, D. H., Lindenmayer, J., McEvoy, J. P., Buckley, P. F., et al. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817e63a5 · Cited by 97
Self-citationCentral Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance
Martins, P. J. F., Haas, M., & Obici, S. (2010) · Diabetes · doi:10.2337/db10-0449 · Cited by 97
The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial
Emsley, R. A., Niehaus, D. J. H., Koen, L., Oosthuizen, P. P., Turner, H. J., Carey, P. D., van Rensburg, S. J., Maritz, J. S., & Murck, H. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.023 · Cited by 97
Treatment Adherence and Long-Term Outcomes
Kane, J. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900026304 · Cited by 97
Haddad, P. M., Taylor, M., & Niaz, O. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s20 · Cited by 96
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis
Need, A. C., Keefe, R. S. E., Ge, D., Grossman, I., Dickson, S., McEvoy, J. P., & Goldstein, D. B. (2009) · European Journal of Human Genetics · doi:10.1038/ejhg.2008.264 · Cited by 96
Self-citationHasnain, M., Vieweg, W. V. R., & Hollett, B. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.07.2577 · Cited by 96
Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers
Sacher, J., Mossaheb, N., Spindelegger, C., Klein, N., Geiss-Granadia, T., Sauermann, R., Lackner, E., Joukhadar, C., Müller, M., & Kasper, S. F. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301541 · Cited by 96
Mackin, P., Bishop, D. R., & Watkinson, H. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-28 · Cited by 96
Rook, J. M., Choi, D., Foster, D. J., & Conn, P. J. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s55104 · Cited by 95
Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs
Tarsy, D., Lungu, C., & Baldessarini, R. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00043-4 · Cited by 95
Upcoming Agents for the Treatment of Schizophrenia
Bishara, D., & Taylor, D. M. (2008) · Drugs · doi:10.2165/0003495-200868160-00002 · Cited by 95
Trifirò, G., Spina, E., & Gambassi, G. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.017 · Cited by 95
Epilepsy and Dementia in the Elderly
Hommet, C., Mondon, K., Camus, V., de Toffol, B., & Constans, T. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000119103 · Cited by 95
Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 95
The influence of therapeutic alliance and insight on medication adherence in schizophrenia
Misdrahi, D., Petit, M., Blanc, O., Bayle, F., & Llorca, P. (2011) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2011.598556 · Cited by 95
Potkin, S. G., Gharabawi, G. M., Greenspan, A. J., Mahmoud, R. A., Kosik‐Gonzalez, C., Rupnow, M. F. T., Bossie, C. A., Davidson, M., Burtea, V., & ZHU, Y. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.027 · Cited by 95
Gómez‐Revuelta, M., Pelayo‐Terán, J. M., Juncal‐Ruíz, M., Vázquez-Bourgón, J., Suárez‐Pinilla, P., Romero-Jiménez, R., Setién‐Suero, E., Ayesa‐Arriola, R., & Crespo‐Facorro, B. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa004 · Cited by 94
Egerton, A., Murphy, A., Donocik, J. G., Anton, A., Barker, G. J., Collier, T., Deakin, J. F. W., Drake, R., Eliasson, E. T., Emsley, R., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa128 · Cited by 94
Management of Schizophrenia in Children and Adolescents
Masi, G., & Liboni, F. (2011) · Drugs · doi:10.2165/11585350-000000000-00000 · Cited by 94
Howes, O. D., Wheeler, M. J., Pilowsky, L. S., Landau, S., Murray, R. M., & Smith, S. M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0302 · Cited by 94
Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181694f5a · Cited by 94
Yolken, R. H., Torrey, Ε. F., Lieberman, J. A., Yang, S., & Dickerson, F. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.020 · Cited by 94
Self-citationPsychotropic medication use among nursing home residents in Austria: a cross-sectional study
Mann, E., Köpke, S., Haastert, B., Pitkälä, K. H., & Meyer, G. (2009) · BMC Geriatrics · doi:10.1186/1471-2318-9-18 · Cited by 94
Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents
Caccia, S. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0024-6 · Cited by 94
Thuné-Boyle, I. C. V., Iliffe, S., Cerga-Pashoja, A., Lowery, D., & Warner, J. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002365 · Cited by 93
Riordan, H., Antonini, P., & Murphy, M. F. (2011) · Europe PMC (PubMed Central) · Cited by 93
Gunes, A., Melkersson, K. I., Scordo, M. G., & Dahl, M. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31819302c3 · Cited by 93
Does abnormal sleep impair memory consolidation in schizophrenia?
Manoach, D. S. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.021.2009 · Cited by 93
Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use?
Arranz, M. J., & Kapur, S. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn114 · Cited by 93
Restarting Clozapine after Neutropenia
Whiskey, E., & Taylor, D. M. (2007) · CNS Drugs · doi:10.2165/00023210-200721010-00003 · Cited by 93
Revitalizing Psychiatric Therapeutics
Hyman, S. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.181 · Cited by 92
Ujkaj, M., Davidoff, D. A., Seiner, S. J., Ellison, J. M., Harper, D. G., & Forester, B. P. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3182051bbc · Cited by 92
American psychiatry in the new millennium: a critical appraisal
Scull, A. T. (2021) · Psychological Medicine · doi:10.1017/s0033291721001975 · Cited by 94
Bishop, J. R., Zhang, L., & Lizano, P. L. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000321 · Cited by 92
Akathisia and second-generation antipsychotic drugs
Kumar, R., & Sachdev, P. S. (2009) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32832a16da · Cited by 92
Fleischhacker, W. W., SIU, C. O., Bodén, R., Pappadopulos, E. A., Karayal, O. N., Kahn, R. S., & the EUFEST study group (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001241 · Cited by 92
Urs, N. M., Snyder, J. C., Jacobsen, J. P. R., Peterson, S. M., & Caron, M. G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215489109 · Cited by 92
The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia
Marder, S. R. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/smarder · Cited by 92
NCAM1 and Neurocognition in Schizophrenia
Sullivan, P. F., Keefe, R. S. E., Lange, L. A., Lange, E. M., Stroup, T. S., Lieberman, J. A., & Maness, P. F. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.07.036 · Cited by 92
Self-citationGaudiano, B. A., Herbert, J. D., & Hayes, S. C. (2010) · Behavior Therapy · doi:10.1016/j.beth.2010.03.001 · Cited by 91
“Pharmacological treatments for psychosis traditionally have focused on reducing the frequency and intensity of psychotic symptoms and have not been shown to be as effective in promoting functional improvement (Juckel & Morosini, 2008; Lieberman et al., 2005).”
BackgroundGrimaldi‐Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Bénichou, J., Falissard, B., Limosin, F., Beaufils, B., Vaïva, G., Verdoux, H., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.022 · Cited by 91
Geographical and temporal variations in clozapine prescription for schizophrenia
Nielsen, J., Røge, R., Schjerning, O., Sørensen, H. J., & Taylor, D. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.003 · Cited by 91
Pharmacogenetics and outcome with antipsychotic drugs
Pouget, J. G., Shams, T. A., Tiwari, A. K., & Müller, D. J. (2014) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2014.16.4/jpouget · Cited by 91
García‐Rizo, C., Fernández-Egea, E., Oliveira, C., Justicia, A., Parellada, E., Bernardo, M., & Kirkpatrick, B. W. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.07.025 · Cited by 91
Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis
Emsley, R. A., Medori, R., Koen, L., Oosthuizen, P., Niehaus, D. J. H., & Rabinowitz, J. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318167269d · Cited by 91
Schizophrenia and the Efficacy of qEEG-Guided Neurofeedback Treatment
Sürmeli, T., Ertem, A., Eralp, E., & Kos, I. H. (2012) · Clinical EEG and Neuroscience · doi:10.1177/1550059411429531 · Cited by 92
Bushe, C., & Shaw, M. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107078281 · Cited by 91
Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): Rationale, Design, and Methods
McCLELLAN, J., SIKICH, L., FINDLING, R. L., FRAZIER, J. A., VITIELLO, B., HLASTALA, S. A., WILLIAMS, E., AMBLER, D., HUNT-HARRISON, T., MALONEY, A. E., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e3180691779 · Cited by 90
Self-citationBauer, M., El-Khalili, N., Datto, C. J., Szamosi, J., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.032 · Cited by 90
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Parellada, E., & Bioque, M. (2016) · CNS Drugs · doi:10.1007/s40263-016-0350-7 · Cited by 90
Correll, C. U., Koblan, K. S., Hopkins, S. C., Li, Y., Dworak, H., GOLDMAN, R. S., & Loebel, A. D. (2021) · Schizophrenia · doi:10.1038/s41537-021-00190-z · Cited by 90
Efficacy of Iloperidone in the Treatment of Schizophrenia
Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181692787 · Cited by 90
Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs
Wierońska, J. M., & Pilc, A. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.02.019 · Cited by 90
Impaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89
Self-citationCardiovascular aspects of antipsychotics
Raedler, T. J. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f46c9 · Cited by 89
Bradshaw, T., & Pedley, R. (2012) · International Journal of Mental Health Nursing · doi:10.1111/j.1447-0349.2012.00818.x · Cited by 89
Obesity in Adolescents with Psychiatric Disorders
Chao, A. M., Wadden, T. A., & Berkowitz, R. I. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-0990-7 · Cited by 89
Metadata
- Authors
- Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., Severe, J., & Hsiao, J. K.
- Affiliations
- New York State Psychiatric Institute (US)
- Duke University (US)
- Yale University (US)
- University of North Carolina at Chapel Hill (US)
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-09-22
- Volume
- 353
- Issue
- 12
- Pages
- 1209-1223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2159155203
- Cited by
- 5,892
- References
- 32
- Citations by year
- 2026: 95 · 2025: 89 · 2024: 135 · 2023: 129 · 2022: 191 · 2021: 166 · 2020: 338 · 2019: 207 · 2018: 211 · 2017: 220 · 2016: 231 · 2015: 277 · 2014: 325 · 2013: 361 · 2012: 379
- FWCI
- 258.86
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Case Western Reserve University
- Foundation of Hope for Research and Treatment of Mental Illness
- Otsuka Pharmaceutical
- National Institutes of Health (n01mh90001-21-0-0)
- University of North Carolina at Chapel Hill
- National Institute of Mental Health (N01 MH90001, MH90001)
- Janssen Pharmaceuticals
- School of Medicine, University of North Carolina at Chapel Hill
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, atypical antipsychotics, typical antipsychotics, perphenazine, olanzapine, quetiapine, risperidone, ziprasidone, treatment discontinuation, treatment efficacy, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, chronic schizophrenia, double-blind comparison, long-term treatment
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Benzodiazepines, Chronic Disease, Dibenzothiazepines, Double-Blind Method, Female, Humans, Lipids, Male, Patient Compliance, Perphenazine, Piperazines, Schizophrenia, Thiazoles, Antipsychotic Agents, Weight Gain, Proportional Hazards Models, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
